Annual EBIT
$1.89 B
+$1.47 B+351.47%
December 31, 2023
Summary
- As of February 11, 2025, RPRX annual earnings before interest & taxes is $1.89 billion, with the most recent change of +$1.47 billion (+351.47%) on December 31, 2023.
- During the last 3 years, RPRX annual EBIT has risen by +$28.26 million (+1.52%).
- RPRX annual EBIT is now -30.87% below its all-time high of $2.73 billion, reached on December 31, 2019.
Performance
RPRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$872.86 M
+$629.47 M+258.63%
September 30, 2024
Summary
- As of February 11, 2025, RPRX quarterly earnings before interest & taxes is $872.86 million, with the most recent change of +$629.47 million (+258.63%) on September 30, 2024.
- Over the past year, RPRX quarterly EBIT has increased by +$832.90 million (+2084.40%).
- RPRX quarterly EBIT is now -42.19% below its all-time high of $1.51 billion, reached on December 31, 2019.
Performance
RPRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$1.92 B
+$704.75 M+57.94%
September 30, 2024
Summary
- As of February 11, 2025, RPRX TTM earnings before interest & taxes is $1.92 billion, with the most recent change of +$704.75 million (+57.94%) on September 30, 2024.
- Over the past year, RPRX TTM EBIT has increased by +$549.86 million (+40.10%).
- RPRX TTM EBIT is now -35.20% below its all-time high of $2.96 billion, reached on September 30, 2020.
Performance
RPRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RPRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +351.5% | +2084.4% | +40.1% |
| 3 y3 years | +1.5% | +2084.4% | +40.1% |
| 5 y5 years | +5.0% | +71.5% | -29.6% |
RPRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +351.5% | at high | +255.0% | at high | +359.6% |
| 5 y | 5-year | -30.9% | +351.5% | -42.2% | +255.0% | -35.2% | +359.6% |
| alltime | all time | -30.9% | +351.5% | -42.2% | +255.0% | -35.2% | +359.6% |
Royalty Pharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $872.86 M(+258.6%) | $1.92 B(+57.9%) |
| Jun 2024 | - | $243.39 M(+509.1%) | $1.22 B(-11.3%) |
| Mar 2024 | - | $39.96 M(-94.8%) | $1.37 B(-27.3%) |
| Dec 2023 | $1.89 B(+351.5%) | $764.84 M(+355.0%) | $1.89 B(+237.4%) |
| Sep 2023 | - | $168.11 M(-57.8%) | $559.36 M(-15.1%) |
| Jun 2023 | - | $398.29 M(-28.4%) | $658.64 M(-17.6%) |
| Mar 2023 | - | $556.04 M(-198.8%) | $798.92 M(+91.1%) |
| Dec 2022 | $418.02 M(-70.3%) | -$563.08 M(-310.6%) | $418.02 M(-61.4%) |
| Sep 2022 | - | $267.39 M(-50.4%) | $1.08 B(+0.1%) |
| Jun 2022 | - | $538.56 M(+207.5%) | $1.08 B(-22.0%) |
| Mar 2022 | - | $175.15 M(+74.0%) | $1.39 B(-1.5%) |
| Dec 2021 | $1.41 B | $100.64 M(-62.2%) | $1.41 B(-17.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $266.12 M(-68.5%) | $1.71 B(-18.5%) |
| Jun 2021 | - | $844.18 M(+329.8%) | $2.10 B(+11.0%) |
| Mar 2021 | - | $196.39 M(-51.4%) | $1.89 B(+1.8%) |
| Dec 2020 | $1.86 B(-31.9%) | $404.47 M(-38.3%) | $1.86 B(-37.3%) |
| Sep 2020 | - | $655.70 M(+3.1%) | $2.96 B(+5.2%) |
| Jun 2020 | - | $636.16 M(+291.1%) | $2.82 B(+16.0%) |
| Mar 2020 | - | $162.68 M(-89.2%) | $2.43 B(-11.0%) |
| Dec 2019 | $2.73 B(+51.9%) | $1.51 B(+196.7%) | $2.73 B(+123.7%) |
| Sep 2019 | - | $508.82 M(+105.2%) | $1.22 B(+71.5%) |
| Jun 2019 | - | $247.94 M(-46.5%) | $711.30 M(+53.5%) |
| Mar 2019 | - | $463.36 M | $463.36 M |
| Dec 2018 | $1.80 B(+13.0%) | - | - |
| Dec 2017 | $1.59 B | - | - |
FAQ
- What is Royalty Pharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for Royalty Pharma?
- What is Royalty Pharma annual EBIT year-on-year change?
- What is Royalty Pharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Royalty Pharma?
- What is Royalty Pharma quarterly EBIT year-on-year change?
- What is Royalty Pharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Royalty Pharma?
- What is Royalty Pharma TTM EBIT year-on-year change?
What is Royalty Pharma annual earnings before interest & taxes?
The current annual EBIT of RPRX is $1.89 B
What is the all time high annual EBIT for Royalty Pharma?
Royalty Pharma all-time high annual earnings before interest & taxes is $2.73 B
What is Royalty Pharma annual EBIT year-on-year change?
Over the past year, RPRX annual earnings before interest & taxes has changed by +$1.47 B (+351.47%)
What is Royalty Pharma quarterly earnings before interest & taxes?
The current quarterly EBIT of RPRX is $872.86 M
What is the all time high quarterly EBIT for Royalty Pharma?
Royalty Pharma all-time high quarterly earnings before interest & taxes is $1.51 B
What is Royalty Pharma quarterly EBIT year-on-year change?
Over the past year, RPRX quarterly earnings before interest & taxes has changed by +$832.90 M (+2084.40%)
What is Royalty Pharma TTM earnings before interest & taxes?
The current TTM EBIT of RPRX is $1.92 B
What is the all time high TTM EBIT for Royalty Pharma?
Royalty Pharma all-time high TTM earnings before interest & taxes is $2.96 B
What is Royalty Pharma TTM EBIT year-on-year change?
Over the past year, RPRX TTM earnings before interest & taxes has changed by +$549.86 M (+40.10%)